Yipinhong subsidiary secures levofloxacin oral solution registration

Guangzhou Yipinhong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Yipinhong Pharmaceutical Group Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for its Levofloxacin Oral Solution. This allows the company to market this drug in the domestic market, enriching its product pipeline and strengthening its competitive position in the anti-infective field.

The drug, classified as a Category 3 chemical medicine, has a specification of 100ml:2.5g and an approval number of H20256184, valid until December 8, 2030. The registration is for domestic production and the product is a prescription drug.

Levofloxacin Oral Solution is indicated for various mild, moderate, and severe infections in adults (≥18 years old) caused by sensitive bacterial strains, including hospital-acquired pneumonia, community-acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, complicated skin and soft tissue infections, chronic bacterial prostatitis, complicated urinary tract infections, acute pyelonephritis, and uncomplicated urinary tract infections. According to Minaiwang data, the sales scale of levofloxacin in Chinese urban and county public hospitals was approximately CNY 401,375 in 2024.